# Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

> **NCT00220402** · PHASE3 · COMPLETED · sponsor: **Pfizer**

## Conditions studied

- Overactive Bladder Syndrome

## Interventions

- **DRUG:** SPM 907

## Key facts

- **NCT ID:** NCT00220402
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** — (—)
- **Last updated:** 2008-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00220402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00220402, "Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00220402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*